Cargando…
Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases
This structured clinical observation includes 28 patients with severe RLS, severe augmentation, and previously frustrating changes of dopaminergic treatment. All were switched from their current dopaminergic regimen to an individually adjusted rotigotine monotherapy; dosages were kept stable for 12...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581243/ https://www.ncbi.nlm.nih.gov/pubmed/23471225 http://dx.doi.org/10.1155/2011/468952 |
_version_ | 1782260392254242816 |
---|---|
author | Godau, Jana Berg, Daniela |
author_facet | Godau, Jana Berg, Daniela |
author_sort | Godau, Jana |
collection | PubMed |
description | This structured clinical observation includes 28 patients with severe RLS, severe augmentation, and previously frustrating changes of dopaminergic treatment. All were switched from their current dopaminergic regimen to an individually adjusted rotigotine monotherapy; dosages were kept stable for 12 months. Follow-up exams were performed after 1, 3, 6, and 12 months. Severity of RLS symptoms (IRLS), augmentation (ASRS), depressive symptoms (BDI), and daytime sleepiness (ESS) were assessed at all visits. Median rotigotine dose was 4 mg. 27 of the 28 patients showed a major to complete reduction of RLS symptoms. IRLS and BDI scores (both P < .001), but not ESS scores, were significantly reduced. IRLS and BDI amelioration remained stable over the 12-month follow-up period. Augmentation occurred in only one patient. 71.4% suffered at least one mostly mild side effect; most common were increased appetite with compulsive eating (42.9%), application site reaction (28.6%), and nausea (14.3%). In the clinical setting, rotigotine seems to be valuable for the long-term treatment of patients with severe RLS and augmentation. |
format | Online Article Text |
id | pubmed-3581243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35812432013-03-06 Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases Godau, Jana Berg, Daniela Sleep Disord Case Report This structured clinical observation includes 28 patients with severe RLS, severe augmentation, and previously frustrating changes of dopaminergic treatment. All were switched from their current dopaminergic regimen to an individually adjusted rotigotine monotherapy; dosages were kept stable for 12 months. Follow-up exams were performed after 1, 3, 6, and 12 months. Severity of RLS symptoms (IRLS), augmentation (ASRS), depressive symptoms (BDI), and daytime sleepiness (ESS) were assessed at all visits. Median rotigotine dose was 4 mg. 27 of the 28 patients showed a major to complete reduction of RLS symptoms. IRLS and BDI scores (both P < .001), but not ESS scores, were significantly reduced. IRLS and BDI amelioration remained stable over the 12-month follow-up period. Augmentation occurred in only one patient. 71.4% suffered at least one mostly mild side effect; most common were increased appetite with compulsive eating (42.9%), application site reaction (28.6%), and nausea (14.3%). In the clinical setting, rotigotine seems to be valuable for the long-term treatment of patients with severe RLS and augmentation. Hindawi Publishing Corporation 2011 2011-01-23 /pmc/articles/PMC3581243/ /pubmed/23471225 http://dx.doi.org/10.1155/2011/468952 Text en Copyright © 2011 J. Godau and D. Berg. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Godau, Jana Berg, Daniela Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases |
title | Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases |
title_full | Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases |
title_fullStr | Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases |
title_full_unstemmed | Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases |
title_short | Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases |
title_sort | rotigotine in the long-term treatment of severe rls with augmentation: a series of 28 cases |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581243/ https://www.ncbi.nlm.nih.gov/pubmed/23471225 http://dx.doi.org/10.1155/2011/468952 |
work_keys_str_mv | AT godaujana rotigotineinthelongtermtreatmentofsevererlswithaugmentationaseriesof28cases AT bergdaniela rotigotineinthelongtermtreatmentofsevererlswithaugmentationaseriesof28cases |